Elevance Health (ELV) Stock Overview
Operates as a health benefits company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
ELV passed our risk checks.
ELV Community Fair Values
Create NarrativeSee what 188 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$390.54
FV
3.6% overvalued intrinsic discount6.79%
Revenue growth p.a.
201
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Elevance Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$404.56 |
| 52 Week High | US$426.98 |
| 52 Week Low | US$273.71 |
| Beta | 0.68 |
| 1 Month Change | 5.98% |
| 3 Month Change | 40.53% |
| 1 Year Change | 6.20% |
| 3 Year Change | -7.28% |
| 5 Year Change | 6.90% |
| Change since IPO | 1,878.29% |
Recent News & Updates
Narrative Update • Jun 01
ELV: CMS Sanction Progress Will Support Government Margin Recovery And Repricing
Analysts have lifted the fair value estimate for Elevance Health from about $442 to roughly $493, reflecting higher Street price targets tied to expectations for ongoing margin recovery in government programs and steadier performance in the commercial business. Analyst Commentary Bullish analysts have been lifting their fair value assumptions for Elevance Health, pointing to a mix of margin recovery in government programs, steadier commercial trends, and company specific execution on regulatory issues.Seeking Alpha • Jun 01
Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)
Summary Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results. Q1 2026 saw ELV revenue up 1.5% to $49.5bn, adjusted EPS up 5.1% to $12.58, and a benefit expense ratio improvement to 86.8%. ELV raised 2026 adjusted EPS guidance to at least $26.75 and expects a return to 12% adjusted EPS growth in 2027. I now view ELV as a Buy, with sector tailwinds, AI-driven efficiencies, and a 1.75% yield supporting further upside from current valuations. Read the full article on Seeking Alpha
Narrative Update • May 17
ELV: Medicaid And CMS Sanctions Risk Will Pressure 2026 Earnings Visibility
Analysts have made only modest adjustments to Elevance Health's assumptions, keeping fair value at $331.00 while slightly revising the discount rate, revenue growth, profit margin, and future P/E as they weigh recent upgrades, price target changes, and commentary around Medicaid margins and Centers for Medicare and Medicaid Services sanctions. Analyst Commentary Recent Street research around Elevance Health has centered on how the company is managing Medicaid margins, responding to Centers for Medicare and Medicaid Services sanctions, and executing on its 2026 guidance.Narrative Update • Apr 30
ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility
The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street. Analyst Commentary Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance.Recent updates
Narrative Update • Jun 01
ELV: CMS Sanction Progress Will Support Government Margin Recovery And Repricing
Analysts have lifted the fair value estimate for Elevance Health from about $442 to roughly $493, reflecting higher Street price targets tied to expectations for ongoing margin recovery in government programs and steadier performance in the commercial business. Analyst Commentary Bullish analysts have been lifting their fair value assumptions for Elevance Health, pointing to a mix of margin recovery in government programs, steadier commercial trends, and company specific execution on regulatory issues.Seeking Alpha • Jun 01
Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)
Summary Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results. Q1 2026 saw ELV revenue up 1.5% to $49.5bn, adjusted EPS up 5.1% to $12.58, and a benefit expense ratio improvement to 86.8%. ELV raised 2026 adjusted EPS guidance to at least $26.75 and expects a return to 12% adjusted EPS growth in 2027. I now view ELV as a Buy, with sector tailwinds, AI-driven efficiencies, and a 1.75% yield supporting further upside from current valuations. Read the full article on Seeking AlphaNarrative Update • May 17
ELV: Medicaid And CMS Sanctions Risk Will Pressure 2026 Earnings Visibility
Analysts have made only modest adjustments to Elevance Health's assumptions, keeping fair value at $331.00 while slightly revising the discount rate, revenue growth, profit margin, and future P/E as they weigh recent upgrades, price target changes, and commentary around Medicaid margins and Centers for Medicare and Medicaid Services sanctions. Analyst Commentary Recent Street research around Elevance Health has centered on how the company is managing Medicaid margins, responding to Centers for Medicare and Medicaid Services sanctions, and executing on its 2026 guidance.Narrative Update • Apr 30
ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility
The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street. Analyst Commentary Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance.Narrative Update • Apr 15
ELV: 2026 CMS Sanction Resolution Will Support Medicare Advantage Margin Recovery
Analysts have made a modest downward adjustment to Elevance Health's implied fair value, reflecting recent cuts and mixed revisions to $350 oriented price targets, along with neutral to cautious views on Medicare policy and margin pressure. Analyst Commentary Recent Street research on Elevance Health shows a mix of cautious and constructive views, with several firms revisiting their models around Medicare policy, sanctions and long term guidance.Narrative Update • Apr 01
ELV: 2026 CMS Sanction Clarity Will Drive Medicare Advantage Repricing
Narrative Update The analyst price target for Elevance Health has been reduced by $9.77 to reflect analysts' recalibration of revenue growth and valuation assumptions after recent CMS related headlines. This revision still incorporates company guidance indicating that any sanctions related impact is already captured in 2026 expectations.Narrative Update • Mar 17
ELV: 2026 Guidance And Medicare Advantage Outlook Will Support Earnings Visibility
Elevance Health's analyst fair value estimate has shifted from $320 to $332, as analysts factor in updated price targets that reflect recent CMS related headlines, reiterated 2026 guidance, and a more mixed view on Medicare Advantage and government programs. Analyst Commentary Recent Street research on Elevance Health shows a split view.Narrative Update • Mar 03
ELV: Medicare Advantage Upside And Policy Tailwinds Will Drive Repricing
Analysts have trimmed their aggregate price target for Elevance Health by updating fair value to about $451.95 from roughly $495.70. This reflects more conservative assumptions on revenue growth and profit margins, partly offset by a slightly higher future P/E multiple and recent mixed research that includes both target cuts and a few upward revisions.
Narrative Update • Feb 17
ELV: Medicare Advantage Policy Path Will Support Future Margin Recovery Potential
Analysts have nudged their fair value estimate for Elevance Health slightly lower to $387.85 from $389.55, reflecting recent mixed price target changes and updated views on Medicare Advantage and broader managed care policy risks and opportunities. Analyst Commentary Recent research on Elevance Health reflects a mix of optimism about medium term growth drivers and caution around policy and utilization risks, which feeds directly into the modest trim to fair value.Narrative Update • Feb 03
ELV: Medicare Advantage Policy Path Will Drive Future Margin Recovery Potential
The analyst price target for Elevance Health has been trimmed by about $5 to $389.55 as analysts factor in softer revenue growth and profit margin assumptions, partially offset by a slightly higher future P/E multiple and recent mixed target changes across the Street. Analyst Commentary Recent research on Elevance Health reflects a mix of optimism and caution, with several firms adjusting price targets in both directions and updating views on managed care, Medicare Advantage, and the broader policy backdrop.Narrative Update • Jan 19
ELV: Medicare Advantage And ACA Policy Shifts Will Shape Margin Recovery Prospects
Analysts have lifted their fair value estimate for Elevance Health by about $7 to $394.60 as they factor in higher Street price targets and expectations for more supportive trends in Medicare Advantage and healthcare exchanges, alongside slightly adjusted assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Elevance Health points to an overall constructive tone, with several firms revisiting their models and price targets as they reassess earnings potential in Medicare Advantage, exchanges, and related services.Narrative Update • Jan 05
ELV: ACA Subsidy Uncertainty Will Pressure Membership And Earnings Visibility
Analysts now place fair value for Elevance Health at $320, down from $331, reflecting updated price targets that balance slightly higher revenue growth and margin assumptions with a lower future P/E and regulatory and membership headwinds highlighted in recent research. Analyst Commentary Recent research on Elevance Health points to a mixed setup, with some firms lifting price targets while others trim expectations or initiate coverage with a more cautious stance.Narrative Update • Dec 15
ELV: Future Policy Shifts Will Shape ACA Membership And Earnings Risk
Analysts have modestly raised our fair value estimate for Elevance Health to $331 from $297 per share. This reflects a higher future P/E assumption despite trimming long term revenue growth and margin expectations in light of evolving regulatory and membership headwinds highlighted in recent Street research.Narrative Update • Nov 29
ELV: Margin Recovery From Medicaid Pressures Will Unfold Amid Regulatory Shifts
Analysts have raised their price target for Elevance Health by approximately $1 to $387, citing expectations for steady growth along with a balanced outlook for earnings and margin recovery in a challenging managed care environment. Analyst Commentary Elevance Health has attracted a range of perspectives from Wall Street as analysts weigh recent developments, upcoming regulatory challenges, and the company’s outlook for earnings growth and operational recovery.Narrative Update • Nov 15
ELV: Margin Recovery In Government Plans Will Drive Long-Term Upside
Analysts have modestly lowered their price target for Elevance Health, reflecting a shift from $389 to $386. This adjustment takes into account ongoing headwinds related to regulatory-driven membership changes and anticipated pressure in government-sponsored business lines.Narrative Update • Nov 01
ELV: Margin Recovery Will Drive Upside Despite ACA Headwinds And Premium Increases
Elevance Health's analyst price target has increased by approximately $14 to $389. Analysts cite firmer profit margin expectations, even though the managed care sector continues to face challenges to revenue growth.Narrative Update • Oct 17
AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability
Analysts have raised their price target for Elevance Health by approximately $14 to $375. This reflects increased earnings visibility and expectations for a sector rotation into healthcare, despite ongoing margin pressures in certain business lines.Narrative Update • Oct 03
AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability
Analysts have reduced their average price target for Elevance Health by $9 to $361. They primarily cite persistent Medicaid challenges, mixed earnings commentary, and a more uncertain cost environment as key drivers of the revision.Narrative Update • Sep 04
AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability
Following disappointing Q2 results and a significant EPS guidance cut for 2025, analysts remain cautious on Elevance Health due to earnings uncertainty and operational risks—despite some offsetting segmental strengths and longer-term positives—resulting in an unchanged consensus price target of $368.44. Analyst Commentary Bearish analysts lowered price targets following Elevance Health’s Q2 report, citing a larger-than-expected EPS guidance cut for 2025, lingering questions about the true earnings floor, and persistent volatility in cost trends.Analysis Article • Jul 29
Positive Sentiment Still Eludes Elevance Health, Inc. (NYSE:ELV) Following 25% Share Price Slump
To the annoyance of some shareholders, Elevance Health, Inc. ( NYSE:ELV ) shares are down a considerable 25% in the...Seeking Alpha • Apr 23
Elevance Health: Carelon Growth Not Fully Appreciated
Summary Elevance Health, Inc.'s Q1 results showed stable Medicare utilization and reaffirmed guidance, in contrast to sector volatility following UnitedHealth Group's rough earnings miss. Medicaid pressures remain, but rate negotiations and targeted acquisitions may support margin recovery by 2026. Carelon Services is growing rapidly, offering diversification away from premium-driven revenue. ELV shares trade at a discount to historical and peer valuations, but I am waiting for a wider margin of safety before adding. Read the full article on Seeking AlphaSeeking Alpha • Apr 15
Elevance Health: A Hidden Gem Amongst Healthcare Turbulence
Summary Elevance Health's resilience in a volatile health insurance market is driven by its fee-based Commercial plans and preventive care initiatives. The company's focus on administrative services only plans shields it from rising medical costs, benefiting from its 27.2 million fee-based members. Elevance's Total Health, Total You program reduces costly inpatient admissions, enhancing client retention and allowing capital deployment for shareholder returns. Despite regulatory challenges in Medicare and Medicaid, Elevance's disciplined capital management and share buybacks position it for future growth and outsized investor returns. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Elevance Health: Add A Little Bit Of Health To Your Defensive Portfolio
Summary Elevance Health remains a buy with its strong fundamentals. An added bonus is its defensive nature during the tariff wars. Regulatory changes under Trump's administration and AI integration are key factors influencing ELV's future growth and efficiency improvements. Valuation remains attractive at a 10-year low PE of 11.9X, with a medium-term price target of $490 and a long-term target of $600. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Maximizing Returns: 3 Compelling Reasons To Invest In Elevance Health Now
Summary Due to heightened political uncertainty, health insurer and pharmacy benefit manager, Elevance Health, continues to be shunned by the market. While I focused on the challenges and risks in my last article, in this update, I give three reasons why I feel comfortable taking a contrarian position with ELV stock. Given that Elevance is in financially very healthy shape and is strongly profitable, there is obviously a large margin of safety from an operational perspective. The valuation of Elevance shares also implies a significant margin of safety, as it is hard to imagine the currently priced-in scenario materializing. I feel very comfortable adding to my ELV stock position at $400, although I am nonetheless practicing proper risk management. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Elevance Health: Trading At Depressed Levels, So We Added Modestly
Summary Elevance Health shares fell 21% in 2024 due to weak fundamental performance, with revenue growing low-single-digits and flat earnings per share. The company is expanding its non-insurance capabilities, like CarelonRx and Carelon Services, to boost long-term growth despite current lack of diversification. Medicaid business suffered from pandemic-related membership declines and higher-acuity members, but recovery is expected as states adjust rates. Despite recent execution issues, Elevance's franchise remains strong; shares were added during price weakness, anticipating solid earnings growth in the future. Read the full article on Seeking AlphaSeeking Alpha • Jan 23
Elevance Health Q4 2024 Earnings: Managed Care Continues To Impress
Summary Despite a 29% drop in Elevance Health's stock, I maintain a strong buy rating due to a DCF price target of $549.60, indicating 43% upside. ELV's shift towards managed care, with strong industry tailwinds, supports sustainable margin expansion and revenue growth, making it a compelling investment. Regulatory risks around Pharmacy Benefit Management are mitigated by CarelonRx's diversified revenue streams and a healthy margin of safety in my modeling. The recent price dip presents an exceptional buying opportunity, with Wall Street also bullish, averaging a price target of $500.87, a 30% upside. Read the full article on Seeking AlphaNew Narrative • Jan 08
ELV Market Outlook
This industry includes companies primarily engaged in providing health insurance products, managed care plans, and related healthcare services. These companies play a critical role in financing and maSeeking Alpha • Dec 26
Elevance Health Is An Undervalued Healthcare Juggernaut
Summary Elevance Health is a strong buy despite a 30% stock decline, due to its solid fundamentals and market position in the health insurance industry. The company benefits from secular trends like an aging population and increased life expectancy, driving long-term demand for healthcare services. Key risks include rising healthcare costs and a shrinking Medicaid member base, impacting margins and free cash flow. Despite short-term headwinds, Elevance's undervaluation, strong financials, and potential for future growth make it an attractive investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Elevance Health: A Quality Underpriced Stock Returning To Health
Summary Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration. Comparing ELV to UnitedHealth Group, ELV has higher expected growth and a lower PE, suggesting undervaluation and a price target of $490. Read the full article on Seeking AlphaShareholder Returns
| ELV | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.4% | 6.6% | -4.1% |
| 1Y | 6.2% | 18.5% | 20.6% |
Return vs Industry: ELV underperformed the US Healthcare industry which returned 18.5% over the past year.
Return vs Market: ELV underperformed the US Market which returned 20.6% over the past year.
Price Volatility
| ELV volatility | |
|---|---|
| ELV Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 96,615 | Gail Boudreaux | www.elevancehealth.com |
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
Elevance Health, Inc. Fundamentals Summary
| ELV fundamental statistics | |
|---|---|
| Market cap | US$92.17b |
| Earnings (TTM) | US$5.24b |
| Revenue (TTM) | US$200.42b |
16.8x
P/E Ratio0.4x
P/S RatioIs ELV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELV income statement (TTM) | |
|---|---|
| Revenue | US$200.42b |
| Cost of Revenue | US$148.53b |
| Gross Profit | US$51.89b |
| Other Expenses | US$46.65b |
| Earnings | US$5.24b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.14 |
| Gross Margin | 25.89% |
| Net Profit Margin | 2.62% |
| Debt/Equity Ratio | 72.3% |
How did ELV perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield29%
Payout RatioDoes ELV pay a reliable dividends?
See ELV dividend history and benchmarks| Elevance Health dividend dates | |
|---|---|
| Ex Dividend Date | Jun 10 2026 |
| Dividend Pay Date | Jun 25 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 14 days |
Does ELV pay a reliable dividends?
See ELV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 08:50 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elevance Health, Inc. is covered by 37 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |